← Leaderboards
Takahisa Kanekiyo
North Dakota State University
$19,312,429
Attributed
$23,507,689
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10.6M · FY2016–25$20M$15M$10M$5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$49,371,242 · 15
By mechanism
U19$32,687,453 · 4
RF1$8,565,333 · 4
R01$5,643,235 · 4
R56$1,614,471 · 1
R21$860,750 · 2
Top collaborators
- Jagdish Singh13 shared
- Alison M Goate4 shared
- David M Holtzman4 shared
- Rui Chang2 shared
- Elizabeth M Bradshaw1 shared
Most similar at North Dakota State University
Same institution · by research overlap
- Jagdish Singh$4,468,047
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseasePathway InteractionsBrainMouse ModelAgingApolipoprotein EPropertyGenesElderlyMediatingCell TypeAstrocytesCellsDesignDementiaAmyloid Beta-ProteinPathogenicityPathogenesisProtein IsoformsGenotypeImpaired CognitionPhenotypeNeurons
Grant awards (42)
Biology and pathobiology of apoE in aging and Alzheimer's disease$6,293,390
U19 · FY2025 · AG · contact PI
Administrative Core$1,077,576
U19 · FY2025 · AG · contact PI
Therapeutic Strategy to Treat Alzheimer's Disease by VGF Delivery into Brain$606,012
R01 · FY2025 · AG
Enhanced APOE2 Expression into Brain for Therapeutic Strategy for Alzheimer's Disease$515,197
R01 · FY2025 · AG
Biomarker Core$473,274
U19 · FY2025 · AG · contact PI
Impact of vascular apoE in aging and AD$401,609
U19 · FY2025 · AG · contact PI
Endothelial cell senescence and APOE4 in vascular cognitive impairment and dementia$383,425
R01 · FY2025 · AG · contact PI
Biology and pathobiology of apoE in aging and Alzheimer's disease$6,474,838
U19 · FY2024 · AG · contact PI
Administrative Core$728,276
U19 · FY2024 · AG · contact PI
Therapeutic Strategy to Treat Alzheimer's Disease by VGF Delivery into Brain$580,803
R01 · FY2024 · AG
Enhanced APOE2 Expression into Brain for Therapeutic Strategy for Alzheimer's Disease$525,712
R01 · FY2024 · AG
Impact of vascular apoE in aging and AD$467,827
U19 · FY2024 · AG · contact PI
Endothelial cell senescence and APOE4 in vascular cognitive impairment and dementia$391,250
R01 · FY2024 · AG · contact PI
Biomarker Core$380,924
U19 · FY2024 · AG · contact PI
Biology and pathobiology of apoE in aging and Alzheimer's disease$6,523,942
U19 · FY2023 · AG · contact PI
Neuronal ABCA7 loss of function and Alzheimerâs disease$2,063,098
RF1 · FY2023 · AG · contact PI
Therapeutic Strategy to Treat Alzheimer's Disease by VGF Delivery into Brain$600,211
R01 · FY2023 · AG
Impact of vascular apoE in aging and AD$547,750
U19 · FY2023 · AG · contact PI
Biomarker Core$463,716
U19 · FY2023 · AG · contact PI
Administrative Core$391,750
U19 · FY2023 · AG · contact PI
Biology and pathobiology of apoE in aging and Alzheimer's disease$6,571,383
U19 · FY2022 · AG · contact PI
Impact of vascular apoE in aging and AD$547,750
U19 · FY2022 · AG · contact PI
Biomarker Core$467,073
U19 · FY2022 · AG · contact PI
Administrative Core$391,750
U19 · FY2022 · AG · contact PI
Enhanced APOE2 Expression into Brain for Therapeutic Strategy for Alzheimer's Disease$190,981
RF1 · FY2022 · AG
Enhanced APOE2 Expression into Brain for Therapeutic Strategy for Alzheimer's Disease$1,437,570
RF1 · FY2021 · AG
Endothelial cell senescence and APOE4 in vascular cognitive impairment and dementia$1,173,750
RF1 · FY2021 · AG · contact PI
Biomarker Core$484,625
U19 · FY2021 · AG · contact PI
Predictive Networks-based in-silico approach for Precision Medicine-repurposing for Alzheimer's Disease$777,659
R56 · FY2020 · AG
Brain Neurotropic Growth Factor Delivery to Prevent and Treat Alzheimer's Disease$376,875
R01 · FY2020 · AG
Predictive Networks-based in-silico approach for Precision Medicine-repurposing for Alzheimer's Disease$836,812
R56 · FY2019 · AG
Brain Neurotropic Growth Factor Delivery to Prevent and Treat Alzheimerâs Disease$376,875
R01 · FY2019 · AG
Impact of ApoE2 on aging-related conditions$3,476,050
RF1 · FY2018 · AG · contact PI
Brain Neurotropic Growth Factor Delivery to Prevent and Treat Alzheimerâs Disease$376,875
R01 · FY2018 · AG
Impact of ApoE2 on aging-related conditions$223,884
RF1 · FY2018 · AG · contact PI
Pathogenic mechanisms of ABCA7 in Alzheimer's disease$195,625
R21 · FY2018 · AG · contact PI
Apoe based solid nanoparticles for prevention and treatment of Alzheimer's Disease$145,000
R01 · FY2018 · AG
Brain Neurotropic Growth Factor Delivery to Prevent and Treat Alzheimerâs Disease$376,875
R01 · FY2017 · AG
Reverse apoE4 effects by apoE2 expression in Alzheimer's disease$234,750
R21 · FY2017 · AG · contact PI
Pathogenic mechanisms of ABCA7 in Alzheimer's disease$234,750
R21 · FY2017 · AG · contact PI
Brain Neurotropic Growth Factor Delivery to Prevent and Treat Alzheimerâs Disease$388,125
R01 · FY2016 · AG
Reverse apoE4 effects by apoE2 expression in Alzheimer's disease$195,625
R21 · FY2016 · AG · contact PI